Markets:

Overview

News

Currencies

International

Treasuries

Agios Pharmaceuticals, Inc. - Common Stock (NQ:AGIO)

27.49 +0.51 (+1.89%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 3, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Agios Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

12 Health Care Stocks Moving In Monday's Intraday Session ↗

August 04, 2025

Via Benzinga

Traders are paying attention to the gapping stocks in Monday's session. ↗

August 04, 2025

Let's delve into the US markets on Monday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.

Via Chartmill

What's going on in today's pre-market session ↗

August 04, 2025

As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.

Via Chartmill

Earnings Scheduled For July 31, 2025 ↗

July 31, 2025

Via Benzinga

Earnings Scheduled For May 1, 2025 ↗

May 01, 2025

Via Benzinga

An Overview of Agios Pharmaceuticals's Earnings ↗

April 30, 2025

Via Benzinga

Earnings Scheduled For February 13, 2025 ↗

February 13, 2025

Via Benzinga

Analyst Ratings For Agios Pharmaceuticals ↗

December 10, 2024

Via Benzinga

Deep Dive Into Alnylam Pharmaceuticals Stock: Analyst Perspectives (6 Ratings) ↗

November 01, 2024

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

August 04, 2025

Via Benzinga

Agios (AGIO) Q2 Revenue Jumps 45% ↗

August 01, 2025

Via The Motley Fool

Topics Intellectual Property

Agios Pharmaceuticals Inc (NASDAQ:AGIO) Reports Mixed Q2 2025 Results: Revenue Beat but Wider EPS Loss ↗

July 31, 2025

Agios Pharmaceuticals (AGIO) reported Q2 2025 revenue of $12.46M, beating estimates, but EPS of -$1.93 missed forecasts. Shares fell 10.66% pre-market amid mixed financials and ongoing rare disease...

Via Chartmill

Agios Pharmaceuticals Reveals Encouraging Data From Rare Blood Disorder Study In Younger Patients Aged Below 18 Years ↗

February 13, 2025

Agios' mitapivat met its primary endpoint in a Phase 3 trial for PK deficiency in children. The company plans a marketing application based on the results.

Via Benzinga

Tesla, Micron, Broadcom, MARA Holdings And Other Big Stocks Moving Higher On Monday ↗

December 16, 2024

Via Benzinga

Earnings Preview: Agios Pharmaceuticals ↗

October 30, 2024

Via Benzinga

4 Analysts Have This To Say About Agios Pharmaceuticals ↗

October 10, 2024

Via Benzinga

Agios Crashes 19% After A Surprise Side Effect Hammered Its 'Very Safe' Drug ↗

December 09, 2024

The company is currently seeking approval for its thalassemia treatment in four regions.

Via Investor's Business Daily

This HP Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday ↗

September 27, 2024

Via Benzinga

Micron To $150? Here Are 10 Top Analyst Forecasts For Friday ↗

September 27, 2024

Via Benzinga

Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit. ↗

September 26, 2024

Pfizer stock dipped Thursday after the company voluntarily pulled its sickle cell drug, Oxbryta, from the market following patient deaths.

Via Investor's Business Daily

Agios Pharmaceuticals' Rare Blood Disorder Drug Misses Primary Goal In Pediatric Study, Stock Slides ↗

August 01, 2024

Agios Pharmaceuticals' Phase 3 ACTIVATE-KidsT study results reveal that mitapivat achieved a 28.1% transfusion reduction in children with PK deficiency compared to 11.8% with placebo. Secondary...

Via Benzinga

Expert Ratings For Agios Pharmaceuticals ↗

June 17, 2024

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

June 13, 2024

Via Benzinga

Novavax And Agios Pharmaceuticals Were Among The 10 Biggest Mid-Cap Gainers Last Week (June 1-June 7): Are These In Your Portfolio? ↗

June 09, 2024

Mid-cap stocks saw significant gains last week, with top performers like AGIO, VRNT, and NVAX, causing analysts to raise their forecasts.

Via Benzinga

June’s Biotech Boom: 3 Stocks to Buy for a Summertime Surge ↗

June 05, 2024

Biotech surge alert! Discover three biotech stocks to buy as they catch up with the market in the rest of 2024.

Via InvestorPlace

Why Is Agios Pharmaceuticals Stock Trading Higher On Monday? ↗

June 03, 2024

Agios Pharmaceuticals shares rose after it announced its Phase 3 ENERGIZE-T study of mitapivat in adults with transfusion-dependent alpha- or beta-thalassemia achieved the primary endpoint of...

Via Benzinga

Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday ↗

June 03, 2024

Via Benzinga

Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

May 28, 2024

Via Benzinga

Nvidia Again Boosts Nasdaq To Record Highs ↗

May 28, 2024

The Nasdaq Composite Index is extending Friday's record highs, with help from Nvidia, which is up 5% at last glance and marking its own all-time highs.

Via Talk Markets

Topics Stocks

Why Is Agios Pharmaceuticals Stock Trading Higher On Tuesday? ↗

May 28, 2024

Agios Pharmaceuticals sells its 15% royalty rights on U.S. net sales of Servier's vorasidenib to Royalty Pharma for $905 million upon FDA approval.

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.